BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.00 Consensus Price Target from Brokerages
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1-year price objective […]
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1-year price objective […]
